The 5-year targets set by the St Vincent Declaration for cardiovascular events in Type 2 diabetes have still not been met, despite efforts to spread the word about the importance of treating cardiovascular risk factors in this population. Perhaps the advent of the thiazolidinediones will allow us to address a fundamental problem in Type 2 diabetes - insulin resistance - and thereby positively affect the raft of risk factors associated with the insulin resistance syndrome. However, adding a new drug to the list of medications taken by many patients with Type 2 diabetes may bring problems of compliance. As the prevalence of Type 2 diabetes increases with age so does that of concomitant diseases. Thus, a typical patient might be taking several tablets for these conditions as well as several for their diabetes and medications to address cardiovascular risk factors/disease too. These elderly patients may also be confused and/or have difficulty in opening the bottles and packets. Poor compliance is perhaps inevitable. Therefore, we should at least try to use agents that need only once daily dosing whenever possible. Fortunately, pioglitazone is such an agent and has the added benefit of being a cost-effective way of reducing HbA1c.
|Number of pages||4|
|Journal||International Journal of Clinical Practice, Supplement|
|Publication status||Published - 11 Oct 2001|